Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review
- 5 September 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 28 (12) , 1865-1875
Abstract
Patients with indeterminate liver nodules, classified as LR‐3 and LR‐4 observations per the Liver Imaging Reporting and Data System, are at risk of developing hepatocellular carcinoma (HCC), but risk estimates remain imprecise. We conducted a systematic review of Ovid MEDLINE, EMBASE, and Cochrane databases from inception to December 2021 to identify cohort studies examining HCC incidence among patients with LR‐3 or LR‐4 observations on computed tomography (CT) or magnetic resonance imaging (MRI). Predictors of HCC were abstracted from each study, when available. Of 13 total studies, nine conducted LR‐3 observation‐level analyses, with the proportions of incident HCC ranging from 1.2% to 12.5% at 12 months and 4.2% to 44.4% during longer study follow‐up. Among three studies with patient‐level analyses, 8%–22.2% of patients with LR‐3 lesions developed LR‐4 observations and 11.1%–24.5% developed HCC. Among nine studies conducting LR‐4 observation‐level analyses, incident HCC ranged from 30.8% to 44.0% at 12 months and 30.9% to 71.0% during study follow‐up; conversely, 6%–42% of observations were downgraded to LR‐3 or lower. Patient‐level factors associated with HCC included older age, male sex, higher alpha‐fetoprotein levels, viral etiology, and prior history of HCC; observation‐level factors included maximum diameter, threshold growth, T2 hyperintensity, and visibility on ultrasound. Studies were limited by small sample sizes, inclusion of patients with prior HCC, short follow‐up duration, and failure to account for clustering of observations in patients or competing risks of transplantation and death. LR‐3 and LR‐4 observations have elevated but variable risks of HCC. Higher quality studies are necessary to identify high‐risk patients who warrant close CT or MRI‐based follow‐up.Keywords
This publication has 34 references indexed in Scilit:
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysisGastroenterology, 2018
- Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative studyEuropean Radiology, 2018
- Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader StudyRadiology, 2018
- Diagnostic Performance of Gadoxetic Acid–enhanced Liver MR Imaging versus Multidetector CT in the Detection of Dysplastic Nodules and Early Hepatocellular CarcinomaRadiology, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017
- Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5Journal of Magnetic Resonance Imaging, 2017
- Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR ImagingRadiology, 2016
- Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysisPLOS Medicine, 2014
- Indeterminate Observations (Liver Imaging Reporting and Data System Category 3) on MRI in the Cirrhotic Liver: Fate and Clinical ImplicationsAmerican Journal of Roentgenology, 2013